blue cross blue shield and glp 1 of Michigan won't cover popular weight-loss drugs blue cross blue shield of

CJC-1295/Ipamorelin = more pronounced, particularly in active patients

Direct evidence for GLP-1s as primary treatments for hot flashes is currently limited

In addition to the above findings, several studies have shown that GLP-1RA therapy results in larger proportions of patients achieving 5% and 10% body weight loss than with placebo (Table 1)

#Neuroscience #MBA #EquityResearch #Biotech #BiotechEquityResearch #Ketamine To view or add a comment, sign in In light of the recent interest in dopamine agonists as a treatment of depression, I am curious whether this patient population as well is at risk for impulse control disorder Can dopaminergic medications affect impulse control